Abstract:Abstract Background Patients with severe mental illness (SMI) loose 15–20 years of life due to cardiovascular disease. Much of the metabolic risk, including high rates of type 2 diabetes (T2D) is accrued early on in the illness, highlighting the need for early intervention strategies to target modifiable cardiovascular risk factors. Beyond cardiovascular (CV) risk, metabolic complications have wide-ranging detrimental effects on cognitive performance, medication compliance, and quality of life. There is however an astounding paucity of studies in SMI examining metabolic interventions outside of weight loss. Furthermore, patients with SMI are typically systematically excluded from trials investigating anti-diabetic agents resulting in lack of evidence to guide treatment. Methods Thirty participants with schizophrenia spectrum disorders and co-morbid prediabetes or type 2 diabetes were randomly assigned, in a double-blind fashion to 1500mg/ day of metformin or placebo (2:1 ratio; n=21 metformin and n=9 placebo). Patients had to be overweight or obese, within 5 years of psychosis onset or under the age of 40, and receiving a stable dose of antipsychotics. The primary outcome measures were improvements in glycemia (HbA1c, fasting glucose), and insulin resistance index (Matsuda-derived from glucose tolerance tests and the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)). Secondary outcome measures included changes in weight, fat mass (MRI quantification of hepatic and visceral fat), improvements in cognition, and hippocampal volume (MRI). Data were analyzed using mixed-models methods, and intention to treat analysis. Results Twenty-two patients (n=14 metformin; n=8 placebo) completed the 4-month trial. The metformin group had a significant decrease over time in the HOMA-IR (p=0.043), and fasting blood glucose (p=0.007) vs. placebo. There were no differences between treatment groups in the Matsuda index or HBA1c or any secondary outcome measures. Interestingly, weight loss in both groups correlated significantly with decreases in subcutaneous, but not visceral adipose tissue measured by MRI. Controlling for baseline BMI and fasting blood glucose did not change any study findings. Exploratory correlations between change in metabolic indices and change in clinical and cognitive parameters did not reveal any significant associations. Discussion Independently of weight loss, metformin is effective in improving dysglycemia and insulin sensitivity in a young, severely mentally ill population at very high risk for early CV mortality. Our preliminary findings, however, fail to find an effect of metformin on weight reduction or tissue specific adiposity measures (which in themselves represent key CV risk factors). Notably, patients in this study had overt glucose dysregulation, a sample routinely excluded in studies examining weight loss interventions in SMI. Moreover, meta-analyses of metformin studies in SMI note greater efficacy early in the illness; possibly weight loss effects are blunted once patients develop prediabetes/T2D. It is also possible that this subgroup of patients may benefit from alternate or combined antidiabetic/obesity therapies. In conclusion, our findings support glucose lowering effects of metformin in SMI patients with early onset prediabetes/T2D, but raise the issue of treatment initiation before the development of overt glucose dysregulation to obtain maximum benefits on adiposity reduction. Given the extremely high rates of T2D in patients with SMI, future adequately powered trials are required to examine metabolic interventions in relation to CV risk factors, and also other related domains such as cognitive function in this highly under-researched population.

CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine

CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine

Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial

Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis

M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY

Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial

Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: a Randomized Controlled Trial.

The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression

Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials.

Efficacy of metformin and fermentable fiber combination therapy in adolescents with severe obesity and insulin resistance: study protocol for a double-blind randomized controlled trial

Metabolic Effects Of 7 Antipsychotics On Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial

Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials

Metformin for Treatment of Antipsychotic-Induced Amenorrhea and Weight Gain in Women with First-Episode Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Study

Rationale and design of a randomised controlled trial testing the effect of personalised diet in individuals with pre-diabetes or type 2 diabetes mellitus treated with metformin

Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: a Double-Blind, Placebo-Controlled Study.

Metformin Treatment of Antipsychotic-Induced Dyslipidemia: an Analysis of Two Randomized, Placebo-Controlled Trials.

Dietary fiber and probiotics for the treatment of atypical antipsychotic-induced metabolic side effects: study protocol for a randomized, double-blind, placebo-controlled trial